Home Newsfeeds Evercore ISI Group Upgrades BioCryst Pharmaceuticals to Outperform, Announces $16 Price Target

Evercore ISI Group Upgrades BioCryst Pharmaceuticals to Outperform, Announces $16 Price Target

Evercore ISI Group analyst Liisa Bayko upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from In-Line to Outperform and announces $16 price target.

November 2, 2022

1 minute read

Evercore ISI Group analyst Liisa Bayko upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from In-Line to Outperform and announces $16 price target.

You May Have To Wait Longer For Your New iPhone. Why That’s Good For Apple

September 19, 11:58 AM

BofA analyst Wamsi Mohan reiterated a Buy and price target of $185 on Apple Inc (NASDAQ:AAPL). The re-rating reflected the upgrade cycle in…

February 8, 7:36 AM

(In millions, except per share data) Current Guidance Fiscal 2024 Prior Guidance Fiscal 2024* Guidance

December 16, 12:10 AM

North Korea on Friday said it tested a high-thrust solid-fueled rocket motor that, according to experts, would allow…

June 30, 2:03 PM

Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT)